GRAIL, LLC (GRAL)
NASDAQ: GRAL · IEX Real-Time Price · USD
16.58
-0.34 (-2.01%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Company Description
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection.
The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California.
GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
GRAIL, LLC
| Country | United States |
| Founded | 2016 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,360 |
| CEO | Robert P. Ragusa |
Contact Details
Address: 1525 O'brien Drive Menlo Park, California 94025 United States | |
| Phone | 650-771-9796 |
Stock Details
| Ticker Symbol | GRAL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001699031 |
| ISIN Number | US3847471014 |
| Employer ID | 86-3673636 |
| SIC Code | 8071 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | 8-K/A | [Amend] Current report |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 24, 2024 | 8-K | Current Report |
| Jun 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 12, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K/A | [Amend] Current report |
| Jun 3, 2024 | 8-K | Current Report |
| Jun 3, 2024 | CERT | Certification by an exchange approving securities for listing |
| Jun 3, 2024 | 10-12B/A | Filing |
| May 29, 2024 | 10-12B/A | Filing |